The National Lipid Association’s (NLA) Annual Scientific Session was held May 1-4, 2014 in Orlando, Florida. During the meeting, Atherotech’s Dr.  Krishnaji Kulkarni presented data via poster, which compared the Verticle Lipoprotein Particle™ (VLP) to the Nuclear Magnetic Resonance (NMR) LipoProfile®. Poster presentation details and press release can be found below.

• Poster Title: Low Density Lipoprotein Particle Concentration Measurement by the Vertical Lipoprotein Profile (VLP) Method
• Presentation Date(s): May 2, 2014 from 11:35 AM – 12:35 PM & May 3, 2014 from 12:00 – 1:00 PM
• Where: Portico Hall at the Hyatt Regency Grand Cypress Hotel
• Researchers: Krishnaji Kulkarni, Tiffany Stewart and Elisa Maddox
• Link to NLA’s meeting website: https://www.lipid.org/sessions

ONE-OF-A-KIND VERTICAL LIPOPROTEIN PARTICLE™ TECHNOLOGY SHOWS COMPARABLE RESULTS TO NUCLEAR MAGNETIC RESONANCE LIPOPROFILE® IN DETERMINING RISK OF CORONARY HEART DISEASE

Findings Presented at the 2014 National Lipid Association Scientific Sessions Compared the Efficacy of

Lipoprotein Tests Aimed at Evaluating the “Bad” Cholesterol in the Bloodstream

Orlando, Florida, May 5, 2014 ― Data from a comparison study using the Vertical Lipoprotein Particle™ (VLP) and Nuclear Magnetic Resonance (NMR) LipoProfile®* showed that the VLP™ compared well with the NMR, further demonstrating the benefit of new testing methods for determining a patient’s risk for coronary heart disease (CHD). While low-density lipoprotein cholesterol (LDLc) – also known as the bad cholesterol in the body – is positively associated with CHD, there has been increased interest in identifying new CHD biomarkers. Recent studies suggest that a patient’s LDL particle (LDLp) concentration, which tells exactly how many bad particles are present in the bloodstream, may actually be a better predictor of CHD. In fact, the LDLp measure is advocated by the National Lipid Association (NLA) in both the patient’s initial evaluation and during follow-up of those with an established risk of CHD. The study presented on Friday, May 2, at the 2014 NLA Scientific Sessions in Orlando, Florida compared Atherotech Diagnostic’s new VLP™ technology with the NMR – a test traditionally used to measure LDLp – and found similar results between the two.

“With CHD continuing to be the leading cause of death in the United States, it’s critical that we, as physicians, are offering our patients the most comprehensive and cutting edge tests and technologies available to ensure we are accurately measuring their risk,” said Dr. Peter A. McCullough of Baylor Health Care System in Dallas, Texas. “While NMR paints an accurate picture of LDLp measures, it’s refreshing to see that recent technologies, such as the VLP™, are becoming available and have comparable, if not better, results as we seek new and innovative ways to improve patient outcomes.”

The VLP™ technology was developed by Atherotech Diagnostics Lab, the makers of the VAP® + Lipid Panel – the most accurate and comprehensive lipid profile available to assess cardiometabolic risk factors in three areas: cholesterol, triglycerides and hereditary. As part of the VAP® + Lipid Panel, the VLP™ technology isolates and provides a true LDLp, without interference from other particles – unlike other particle number technologies – so patients know exactly how many of the bad particles are floating around in their bloodstream, resulting in the most accurate risk assessment possible.

For more information on the VAP® + Lipid Panel and VLP™ technology, visit www.Atherotech.com.

*The NMR LipoProfile® is a registered trademark of LipoScience.